Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~(Patient should meet all the criteria)~* JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by WHO diagnostic criteria)~* High risk ET/PV \[age \>60; history of thrombosis\] or low risk disease with symptoms \[recurrent headaches, paresthesias, pruritus\]~* Previously treated with at least one other agent \[hydroxyurea, interferon, anagrelide\] and determined to be either intolerant/resistant~  -≥18 years of age~* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2~* Acceptable pre-study organ function during screening as defined as: Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) unless due to Gilbert's disease or hemolysis, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN, Serum creatinine ≤ 1.5 x ULN~* Women of childbearing potential and males must agree to use adequate contraception (i.e., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a female subject become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediately~* Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~* Meets the criteria for post ET/PV MF as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)~* Blast phase disease (\>20% blasts in the marrow or peripheral blood)~* Acute thrombosis within 3 months of screening~* Uncontrolled intercurrent illness including, but not limited to hepatitis, human immunodeficiency virus (HIV) - positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RG7388 (Type: EXPERIMENTAL): Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388

Based on this trial design, predict the completion outcome and termination type (if applicable).